GRAIL, Inc. (GRAL)

NMS – Цена в реальном времени. Валюта: USD

72.13

-3.35 (-4.44%)

Рынок открыт: Aug 12, 2026, 12:50 PM EDT

75.48

0.00 (0.00%)

Предыдущая сессия: Aug 11, 2026, 7:34 PM EDT

Обзор
Новости
График
Финансы
Дивиденды
Прогноз
Владельцы
Профиль

GRAIL, Inc. (GRAL)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

GRAIL, Inc. (GRAL)

FDA Panel Schedules to Evaluate GRAIL Premarket Approval Application for Multi-Cancer Early Detection Test

US FDA to hold advisory meeting to review Grail's multi-cancer test

GRAIL Announces FDA Advisory Committee Meeting to Review Premarket Approval Application for the Galleri® Multi-Cancer Early Detection Test

GRAIL, Inc. (GRAL) Q2 2026 Earnings Call Transcript

GRAIL Q2 Earnings Call Highlights

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in GRAIL, Inc. of Class Action Lawsuit and Upcoming Deadlines – GRAL

CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds Grail (GRAL) Investors of Securities Class Action Lawsuit Deadline on August 4, 2026

Видео

No Data

Пресс-релизы

GRAIL Announces FDA Advisory Committee Meeting to Review Premarket Approval Application for the Galleri® Multi-Cancer Early Detection Test

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in GRAIL, Inc. of Class Action Lawsuit and Upcoming Deadlines – GRAL

CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds Grail (GRAL) Investors of Securities Class Action Lawsuit Deadline on August 4, 2026

GRAL Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in GRAIL, Inc. Securities Lawsuit - Contact The Gross Law Firm

Search stocks

GRAIL, Inc. (GRAL)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

GRAIL, Inc. (GRAL)

FDA Panel Schedules to Evaluate GRAIL Premarket Approval Application for Multi-Cancer Early Detection Test

US FDA to hold advisory meeting to review Grail's multi-cancer test

GRAIL Announces FDA Advisory Committee Meeting to Review Premarket Approval Application for the Galleri® Multi-Cancer Early Detection Test

GRAIL, Inc. (GRAL) Q2 2026 Earnings Call Transcript

GRAIL Q2 Earnings Call Highlights

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in GRAIL, Inc. of Class Action Lawsuit and Upcoming Deadlines – GRAL

CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds Grail (GRAL) Investors of Securities Class Action Lawsuit Deadline on August 4, 2026

Видео

No Data

Пресс-релизы

GRAIL Announces FDA Advisory Committee Meeting to Review Premarket Approval Application for the Galleri® Multi-Cancer Early Detection Test

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in GRAIL, Inc. of Class Action Lawsuit and Upcoming Deadlines – GRAL

CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds Grail (GRAL) Investors of Securities Class Action Lawsuit Deadline on August 4, 2026

GRAL Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in GRAIL, Inc. Securities Lawsuit - Contact The Gross Law Firm